|Videos|October 17, 2016

Will the Southern States See More Zika Infections?

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response (OPHPR) at the Centers for Disease Control and Prevention (CDC), discusses if southern states will see more Zika infections.

Stephen Redd, MD (RADM, USPHS), Director of the Office of Public Health Preparedness and Response (OPHPR) at the Centers for Disease Control and Prevention (CDC), discusses if southern states will see more Zika infections.

Interview Transcript (slightly modified for readability)

“It’s really hard to say whether [in] the mosquito populations of Texas, Louisiana, or really the southern-most states, whether the sequence of events—where a returning traveler comes home [with an infection] and a mosquito biting that traveler becomes infected and then bit[es] somebody else—[is] likely to occur. I think certainly all the ingredients are there for some limited local transmission to occur.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
FAQ: What You Need to Know About West Nile Virus in 2026
After 2 adults died of West Nile virus in central North Carolina this month, this FAQ explains how the mosquito-borne virus spreads, who faces the greatest risk of severe neuroinvasive disease, and how clinicians can diagnose, manage, and help prevent infection when no vaccine or antiviral treatment exists.